Biometry of phakic IOLs

Article

As the human eye is not geometrically round, biometry is required for proper sizing of phakic IOLs, Dr Liliana Werner told delegates in a presentation entitled 'Phakic IOLs: a report from the pathology lab'.

As the human eye is not geometrically round, biometry is required for proper sizing of phakic IOLs, Dr Liliana Werner told delegates in a presentation entitled ‘Phakic IOLs: a report from the pathology lab’.

Dr Werner presented some cases submitted to the Berlin Eye Research Institute (BERI), where she is director for preclinical research, and conducted a wide-ranging analysis of explantations of various phakic IOL models, including the Icare (Corneal), and the V4 and the Visian ICL (both STAAR Surgical).

She noted that phakic IOLs are increasing in popularity and said that more accurate sizing in the future could potentially reduce postoperative complications, including endothelial cell loss and cataract. Dr Werner went through a series of possible measurements for phakic IOL sizing and found that there were no reliable rules of thumb. Each eye is unique and, even within an individual eye, measurements vary along different meridians.

 

To read OTE's full news coverage of the XXVI congress of the European Society of Cataract & Refractive Surgery, please click here.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.